ArticleJournal of the American Heart Association2026
Targeting Integrin β3 in Endothelial Cells Attenuates Cardiac Fibrosis Through the Calcium-Calmodulin-Dependent Protein Kinase IIα- cAMP-Responsive Element Binding Protein 1 Signaling Axis in Pressure Overload-Induced Heart Failure.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndothelial-to-mesenchymal transition (EndMT) is a key contributor to cardiac fibrosis, yet the role and underlying mechanisms of endothelial integrin β3 (ITGB3) activation in EndMT remain poorly understood. This study aims to explore the involvement of a novel ITGB3- CaMKIIα (calcium-calmodulin-dependent protein kinase IIα)-CREB1 (cAMP-responsive element binding protein) signaling axis in EndMT and to demonstrate that targeting endothelial ITGB3 mitigates pressure overload-induced heart failure (HF) by reducing cardiac fibrosis.
methodsEndothelial-cell-specific ITGB3 knockout mice were subjected to transverse aortic constriction to induce HF. Cardiac function, and the expression of EndMT-associated genes were assessed to evaluate changes in cardiac remodeling. RNA sequencing and primary human endothelial cells and mouse cardiac microvascular endothelial cells were used to investigate downstream mechanisms. Additionally, the ITGB3-specific inhibitor RGDfK was applied in the treatment of HF.
resultsThe activation of ITGB3 was predominantly observed within endothelial cells. Endothelial cell-specific ITGB3 deletion attenuated cardiac dysfunction. Mechanistically, ITGB3 knockdown and CaMKII inhibition reduced CaMKII activation and subsequently lowered nuclear CREB1 phosphorylation levels. Reciprocally, the genetic overexpression of ITGB3 in endothelial cells increased EndMT by activating the CaMKIIα-CREB1 axis. These results were further substantiated by pharmacological studies with the ITGB3 specific cyclic-RGD (Arg-Gly-Asp) peptide inhibitor (RGDfK). RGDfK treatment ameliorated pressure overload-induced cardiac remodeling and markedly improved cardiac function, establishing the disease-specific role of ITGB3 in vivo.
conclusionsThis study demonstrates that endothelial ITGB3 regulates EndMT and contributes to the progression of pressure overload-induced HF, partly through the CaMKIIα-CREB1 signaling pathway. Targeting ITGB3 to inhibit EndMT may offer a promising therapeutic strategy for HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.